I-Ribavirin Drug and Treatment ye-Hepatitis C

I-Agent Antiviral Enamandla

I-Ribavirin iyisidakamizwa esinamandla sokulwa namagciwane esetshenziselwa ukuphatha ukutheleleka okungapheli kwesifo se-hepatitis C. Akuqondwa ngokuphelele ukuthi i-ribavirin kodwa, kodwa ngokujwayelekile, iphazamisa ikhono legciwane lokuphindaphinda. I-Ribavirin ivunyiwe yi-Food and Drug Administration (FDA) yokwelapha i-hepatitis C futhi kuyi-World Health Organisation List of Medicine Essential.

I-Ribavirin idayiswa ngaphansi kwenani lamagama ahlukahlukene wegama, kuhlanganise neCopegus, Rebetol, Ribasphere, ne-RibaPak.

Ukusebenza kwezidakamizwa

Ngaphambi kokusungulwa kwama-anti-virus (DAAs) ngokuqondile-ngo-2013-okubandakanya izidakamizwa zeSovaldi , Harvoni , Daklinza neVikira Phak , phakathi kwabanye-indlela ephumelela kakhulu yokwelapha i-hepatitis C yayihlanganisa inhlanganisela ye-ribavirin ne- peginterferon . I-thérapie ezimbili ziyaziwa ukuthi zinezinga eliphakeme lemiphumela yokwelashwa, ezinye zazo zingaba zijulile. Noma kunjalo, ukwelashwa okuhlanganisiwe kwakwazi ukufeza impendulo eqhubekayo ye-virologic (incazelo yempilo yomuthi) kuma-50% wamacala.

Namuhla, nge-DAA entsha yeklasi, ukusebenzisa i-ribavirin kuye kwehla cishe nakuba kushiwo ezinhlobonhlobo ezithile zokwelashwa, ikakhulukazi ngezinkinga ezithile zofuzo ( genotypes ) wegciwane kanye neziguli ezinezokwelapha zangaphutha ngaphambilini kanye / noma isifo esiyinhloko sesibindi.

Ukulawulwa kwezidakamizwa

I-Ribavirin ithathwa ngomlomo, ngokuvamile emazingeni amancane athathwa amahora angu-12 ehlukile. Izinga elijwayelekile lisuka ku-800 mg kuya ku-1,400 mg ngosuku. Udokotela wakho uzonika ukuthi i-ribavirin engayinikeza ngokusekelwe ku-genotype yegciwane lakho, isisindo sakho, nokuthi yiziphi ezinye izidakamizwa ezizophathwa ngokuthelela.

Imiphumela Yokwelashwa Side Side

Imiphumela emibi ye-ribavirin izohluka kusuka komuntu kuya komuntu, nabanye abantu abaphathayo bayoba nemicimbi encane yokugula lapho abanye bezwa izimpawu abazibona bengenakuziphendulela. Imiphumela emibi kakhulu ehambisana nokusetshenziswa kwe-peginterferon yilezi:

Iziguli zokwelapha ziyokhuluma ngeRuba Rage, efanekiselwa ukucasula okujwayelekile kanye nokuphulukiswa ngokomzwelo ngokomzwelo. Ngesikhathi leli gama libonisa ukuthi imbangela i-ribavirin, ivame ukuhlotshaniswa ne-peginterferon. Ngezinye izikhathi ama-anti-depressants anqunywe ukuze aphathe lesi simo, ikakhulukazi ezigulini ezinezinkinga ezandulela ukugula ngengqondo.

Izindleko zokwelashwa nokufinyelela

Ukwelashwa okuphelele kwe-ribavirin kungabiza kodwa kodwa, ngenhlanhla, ngama-DAA amasha omusha, ubude besikhathi sokwelapha bufushane kakhulu kunangaphambili. Esikhathini esedlule, kungabiza uhla lwe $ 12,000 ukuze uthole inkambo egcwele. Namuhla, kulindeleke ukuba ukhokhe okungaphezulu kuka-$ 2,500 kwenkambo yezinyanga ezingu-12 no-$ 5,000 kwi-course yezinyanga ezingu-16.

I-medicaid, i-Medicare, nomshuwalense wangasese uyovame ukumboza izindleko ze-interferon lapho ukwelashwa kwe-hepatitis C kuvunywa.

Usizo lwe-co-pay lungasetshenziswa ngumkhiqizi wezidakamizwa iziguli ezifanelekile, kanye nezinhlelo zokusiza isiguli (PAPs) eziguli ezingenayo i-uninsured noma ephansi.

Ukuphikisana kokulashwa

I-Ribavirin ibhekwa njengephephile kubantu abaningi, kodwa kunabantu abathile abalashwa khona. I-Ribavirin kufanele igwenywe ngezimo ezilandelayo:

Njalo qiniseka ukuthi udokotela wakho unomlando wakho wezokwelapha ophelele, kufaka phakathi ulwazi mayelana nanoma yikuphi ukutheleleka okungapheli okungenzeka ube nakho (isb., I- HIV , isifo sikashukela) noma yiziphi izinhlelo ozidingayo ukuba ukhulelwe.

Imithombo:

I-Genentech. "I-Copegus: Amaphuzu avelele ekuchazeni ulwazi." Kufinyelelwe kuDisemba 31, 2015.

Merck. "I-Rebetol: Okuvelele kokuchaza ulwazi." Kufinyelelwe kuDisemba 31, 2015.